File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Diabetic Nephropathy: landmark clinical trials and tribulations

TitleDiabetic Nephropathy: landmark clinical trials and tribulations
Authors
Issue Date2015
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
Nephrology Dialysis Transplantation, 2015, v. 31 n. 3, p. 359-368 How to Cite?
AbstractDiabetic nephropathy remains the most common cause of end-stage renal disease worldwide. The current standard of therapy for diabetic nephropathy involves stringent blood pressure control via blockade of the renin–angiotensin system and control of hyperglycemia. Despite these strategies, diabetic nephropathy is still seen to progress relentlessly. A pressing need for novel therapeutic agents has fueled endless basic science research projects and clinical trials in the quest for a more specific therapy. Throughout the process, only a handful of ancillary agents have shown experimental promise and even fewer have demonstrated an impact in human trials. This review article aims to summarize the available data from landmark studies for the main therapeutic approaches investigated.
Persistent Identifierhttp://hdl.handle.net/10722/214359
ISSN
2015 Impact Factor: 4.085
2015 SCImago Journal Rankings: 1.780

 

DC FieldValueLanguage
dc.contributor.authorCHAN, GCW-
dc.contributor.authorTang, SCW-
dc.date.accessioned2015-08-21T11:18:38Z-
dc.date.available2015-08-21T11:18:38Z-
dc.date.issued2015-
dc.identifier.citationNephrology Dialysis Transplantation, 2015, v. 31 n. 3, p. 359-368-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/214359-
dc.description.abstractDiabetic nephropathy remains the most common cause of end-stage renal disease worldwide. The current standard of therapy for diabetic nephropathy involves stringent blood pressure control via blockade of the renin–angiotensin system and control of hyperglycemia. Despite these strategies, diabetic nephropathy is still seen to progress relentlessly. A pressing need for novel therapeutic agents has fueled endless basic science research projects and clinical trials in the quest for a more specific therapy. Throughout the process, only a handful of ancillary agents have shown experimental promise and even fewer have demonstrated an impact in human trials. This review article aims to summarize the available data from landmark studies for the main therapeutic approaches investigated.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.titleDiabetic Nephropathy: landmark clinical trials and tribulations-
dc.typeArticle-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.identifier.doi10.1093/ndt/gfu411-
dc.identifier.pmid25637638-
dc.identifier.hkuros248223-
dc.identifier.hkuros263309-
dc.identifier.volume31-
dc.identifier.issue3-
dc.identifier.spage359-
dc.identifier.epage368-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats